SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
AEON

AEON Biopharma, Inc. (New York Stock Exchange Arca:AEON)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$0.12-$0.01 (-7.59%)
 
Market cap
$6.14M
Insider Score
Health Score
Analyst consensus
Listed since
Jul 24, 2023
Market Cap$6.14M-85.0%
Revenue (ttm)$0
Net Income-$47.62M-1587233.3%
EPS-$3.36-166.6%
Shares Out49.88M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,027,971
Open$0.13
Previous Close$0.13
Day's Range$0.12 - $0.13
52-Week Range$0.11 - $1.45
Beta0.69
AnalystsBuy
Price Targetn/a
Earnings DateMar 29, 2027
-2.33% (1D)
No price history available.

About AEON

AEON Biopharma, Inc. is a biopharmaceutical company primarily engaged in developing therapies based on botulinum toxins, aimed at treating various debilitating medical conditions. Among its key investigational products is ABP-450, a 900 kDa botulinum toxin complex, which is being advanced for therapeutic use in conditions such as migraine, cervical dystonia, and gastroparesis. The entity, originally known as ALPHAEON Corporation, adopted the name AEON Biopharma, Inc. in December 2019. Established in 2012, the company maintains its principal operations from Newport Beach, California.

Address
5 Park Plaza, Irvine, CA, 92614, US
Market Cap
6 million
Employees
8
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Buying
Sold
$0
Bought
$243.46K

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
1 Buy0 Hold0 Sell

1 firm rating AEON in the last 3 months, one vote each. Issuer-paid research is not counted.

Financial Health Score
Weak
From AEON’s reported statements · Q3 2026 (trailing 12 months) · 4 of 5 pillars

Next catalysts

1 Day
-7.59%
5 Days
-23.60%
1 Month
-46.87%
6 Months
-85.75%
1 Year
-85.00%

$AEON stock is featured in our Insider Trades datasets.

→ All Stock Lists

Recently reported changes in AEON holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by AEON's directors and management

Net Shares Purchased by Insiders−2M−1M02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

AEON Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New AEON patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to AEON from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in AEON

VXFVanguard Extended Market ETF$24.80K

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from AEON’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
60% of score
0
Analyst Ratings
40% of score
99
News & Sentiment
No data yet
—

Recent Insider Activity

Buys
1
Sells
0
Buy Value
$243.46K
Distinct Buyers
1

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.